Optimizing Benefit Design and Implementation for Improved PDT Access

Panelists explore how payers choose between pharmacy and medical benefit designs for covering prescription digital therapeutics (PDTs), optimizing patient access and adoption, and discussing why the selected pathway was considered optimal for a specific PDT.

Video content above is prompted by the following questions:

  • How do payers determine the optimal pharmacy vs. medical benefit design to cover prescription digital therapeutics (PDTs) to enhance patient access and adoption?
    • What factors and considerations went into the decision to cover a particular PDT through the pharmacy benefit versus the medical benefit, and why was that pathway determined to be optimal for that specific PDT?
  • What characteristics and factors did Mass Health consider when selecting clinics to prescribe and implement the use of prescription digital therapeutics?
Related Videos
A panel of 5 experts on RSV
A panel of 5 experts on RSV
A panel of 4 experts on CLL
A panel of 4 experts on CLL
Related Content
CH LogoCenter for Biosimilars Logo